Investors in early stage in vitro diagnostic technologies
Who We Are
CS Ventures is the corporate venture fund initiative of Canterbury Scientific Ltd., a leading OEM developer and supplier of high quality in vitro diagnostic controls and calibrators for diabetic and haemoglobinopathy applications worldwide. CS Ventures was established in 2019 to invest in promising IVD opportunities that align with Canterbury Scientific’s existing capabilities and to diversify into applications beyond diabetes mellitus.
What We Are Looking For
CS Ventures makes strategically aligned investments. The type of technology we are interested in is limited to novel IVD technologies, but we are interested in a broad range of applications. We are somewhat flexible regarding deal structure, deal size and stage of development. If you have any questions regarding our interests or want to share your technology, please use the form at the bottom of this page.
Type of Technology: in vitro diagnostic technologies that use any kind of biological reagents and/or controls
Intellectual Property: technology must have protectable IP or the potential for IP. We are interested in novel biomarkers rather than novel platform technologies
Application Area: any disease area where there is an unmet need except diabetes mellitus
Stage of Development: early stage technologies - from proof of concept to Seed stage
Deal Structure: a broad range of investment and partnering structures but with a preference for in-licensing
Geographical Scope: jurisdiction agnostic, we are interested in technologies from all around the world
What We Offer
The size and structure of capital investments CS Ventures makes depends on the specific opportunity. In addition to capital, CS Ventures is supported by Canterbury Scientific’s extensive experience and expertise in upscaling the manufacturing of biologics, quality control management, regulatory processes and approvals, which include FDA and CE Mark. Canterbury Scientific is also well established in the global network of MedTech companies and works closely with many of the major players in the industry. CS Ventures seeks to add value to portfolio technologies using the know how and expertise that Canterbury Scientific has acquired over more than 30 years in the industry.
Robert has an invaluable combination of business, medical and research experience spanning over two decades. A qualified medical practitioner, he obtained his medical degree in London, his PhD in the Netherlands, has worked at Harvard Medical School and held clinical and academic positions at Imperial College, London. Robert is a successful serial life science entrepreneur, having founded and run three biotechnology companies in the UK before establishing the European operations for the New York based company Paramount Biosciences, LLC. Subsequently, Dr Feldman held the role of Entrepreneur in Residence at Imperial Innovations, London. In 2010, he moved to New Zealand as Executive Director of venture investment firm, Pacific Channel.
During his extensive and varied career, Robert has developed a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics and functional preparations in the field of human health. In addition to Robert’s work in the UK and New Zealand, he has also engaged in business development activities in several other countries, including successful licensing deals in Europe, USA, Australia, Russia, South Korea and New Zealand.
Alice has an academic background in both biomedical science and commerce and completed her Masters of Bioscience Enterprise at the University of Auckland, New Zealand. Prior to starting at CS Ventures, Alice worked in life science partnering and R&D consulting, where she worked closely with the external innovation teams of multinational pharmaceutical, consumer health and animal health companies to help them expand their portfolios and pipelines through external collaborations and acquisitions in a range of modalities and stages of development. She also has experience in conducting extensive market analyses and on the operations side, working in accounting/finance teams.